echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Bo Ruikang a round of financing 60 million yuan to accelerate the "brain-machine interface" technology landing clinical

    Bo Ruikang a round of financing 60 million yuan to accelerate the "brain-machine interface" technology landing clinical

    • Last Update: 2021-03-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    , Boracon Technology (Changzhou) Co., Ltd. ("Bo ruikang") officially announced the completion of round A 60 million yuan of financing. Up to now, Bo Ruikang has completed three rounds of financing, the total scale of financing exceeds 100 million yuan. This round of investment by the China-controlled fund lead investment, China Development Kaihang Fund, China Development Frontier Fund, BV Baidu venture capital and investment, Pre-A round leader Kai venture capital continued to follow investment. Huang Xiaoshan, general manager of Bo Ruikang, said that this round of financing funds is mainly used to accelerate the development of clinical products, to promote minimally invasion implanted feedback therapy and brain-computer intelligent active rehabilitation of products landing.
    Based on Tsinghua University's innovative "brain-machine interface" technology, Neuracle is committed to innovative research in neuroscience, psychology, neuro-engineering and other fields to provide professional and complete solutions for the diagnosis, treatment and rehabilitation of clinical neurological diseases. At present, boraycon products are mainly used in brain science research, neuropathy diagnosis and treatment and other fields.
    Brain-computer interface technology is mainly to convert brain signals into external device control commands, on the basis of the brain-computer interface to achieve command output, but also increased the way of information input to the brain, forming a two-way interaction, and ultimately realize brain-computer intelligence - on the basis of the brain and external information interconnection, the realization of brain intelligence and machine intelligence complement each other, co-exist, thus creating a new form of human-machine intelligence. At present, brain-computer interface technology has been widely used in clinical medicine, education and scientific research, game entertainment, consumer electronics and many other fields.
    In the diagnostic application of neurological diseases, Borekang products include electroencephaloelectric and induced power generator (brain function monitor), high-frequency high-conductivity encephalopathic acquisition system, the former is mainly used for epilepsy, cerebral hemorrhage and other neurological diseases diagnosis and monitoring, the latter is mostly used for neurosurgery to assist in positioning. Huang Xiaoshan pointed out that product development should be traction by clinical needs of accurate medical solutions. Take the high-frequency high-conduction encephaloelectrological acquisition system as an example, the product from epilepsy lesions positioning just need to cut in, in the number of channels and sampling rate and other core indicators, high-frequency analysis and positioning function of the innovative program to enhance product competitiveness, at the same time, this is the Ministry of Science and Technology "12th Five-Year Plan" medical device focus special, is currently in the process of widespread popularization.
    Treatment products, Huang Xiaoshan said, Bo Ruikang will focus on minimally invasitable implant feedback therapy and brain-computer intelligent active rehabilitation. Minimally invasive implant feedback therapy is for epilepsy, Alzheimer's and other neurological diseases. Taking Alzheimer's disease as an example, by monitoring and stimulating the memory-related brain regions, the clinical performance of patients can be improved, brain machine intelligent active rehabilitation is mainly for the rehabilitation of nerve diseases such as stroke, "stroke" is actually the death of nerve cells in the motor region, but based on the plasticity of the non-dead part of nerve cells, through the brain interface device to collect and analyze instructions issued by the brain, through the robot arm and other devices to execute commands, the action will also be fed back to the brain, and eventually make the patient "learn" the action again.
    For this investment, Li Chaowen, vice president of investment of China Control Industrial Investment Fund, said: Brain-computer interface is a high-tech cutting-edge technology, but also the main means to study brain science, the realization of brain-computer interconnection, its application in the field of neuropathy treatment, rehabilitation medical treatment, brain science research, consumer electronics and education has broad prospects.
    Dr Los said: "Farxiga has shown good results in treating type 2 diabetes. And these exciting new findings show its potential to reduce the burden of heart failure in people with or without type 2 diabetes. "(Creative Exchange) is
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.